Thursday - June 18, 2026

Category Archives: Science

New Research Peptide Supplier Plans Pharmacy Collaborations to Support Licensed Wellness Clinic Sector

There’s growing interest in peptide therapeutics within wellness medicine, but compliance and supply chain integrity remain critical concerns,” explains a spokesperson for AminoVault. “Our planned collaborations with 503(a) and 503(b) compounding pharmacies will allow licensed prescribers and compounding partners to … Continue reading →

ALK Inhibitors Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s “ALK Inhibitors Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the ALK Inhibitors pipeline landscape. It covers the ALK Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Multiple System Atrophy Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s “Multiple System Atrophy Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Helicobacter Pylori Infection Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s “Helicobacter Pylori Infection Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Helicobacter Pylori Infection pipeline landscape. It covers the Helicobacter Pylori Infection Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Chronic Heart Failure Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s “Chronic Heart Failure Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Chronic Heart Failure pipeline landscape. It covers the Chronic Heart Failure Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Angelman Syndrome Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s “Angelman Syndrome Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Angelman Syndrome pipeline landscape. It covers the Angelman Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Interactive Introvert Journals Launches a Safe Space for Quiet Thinkers to Reflect, Write, and Connect on Their Terms

ATLANTA, GA – October 20, 2025 – In a world that rewards constant sharing and self-promotion, Interactive Introvert Journals has created something rare: a digital sanctuary for deep thinkers who crave reflection over reaction. Designed for introverts, writers, and anyone seeking calm … Continue reading →